Dravet syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:33069OMIM:607208G40.4
Who is this for?
Show terms as
3FDA treatments12Active trials31Specialists8Treatment centers3Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Dravet syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare and serious form of epilepsy that begins in the first year of life. It is caused by changes (mutations) in a gene that helps brain cells communicate properly. When this gene does not work as it should, the brain becomes overly excitable, leading to frequent and hard-to-control seizures. Children with Dravet syndrome typically start having seizures between 5 and 8 months of age. These early seizures are often triggered by fever or a rise in body temperature. Over time, different types of seizures appear, and children may also experience delays in development, problems with balance and walking, and difficulties with learning, behavior, and communication. The condition affects not just the brain but also daily life for the whole family. Treatment focuses on reducing seizures and improving quality of life, since there is currently no cure. Several medications are used, including valproate, clobazam, stiripentol, and cannabidiol (Epidiolex), which is FDA-approved specifically for Dravet syndrome. Fenfluramine (Fintepla) is another FDA-approved option. While seizures often remain difficult to fully control, early diagnosis and the right combination of treatments can make a meaningful difference in a child's development and safety.

Also known as:

Key symptoms:

Frequent seizures that are hard to control with medicationSeizures triggered by fever or overheatingMultiple types of seizures (including full-body convulsions and staring spells)Developmental delays or regression in skillsIntellectual disability ranging from mild to severeProblems with balance, coordination, and walking (often a crouched gait)Behavioral challenges such as hyperactivity, impulsivity, or autism-like traitsDifficulty with speech and languageSleep problemsSensitivity to light (photosensitivity)Increased risk of sudden unexpected death in epilepsy (SUDEP)

Clinical phenotype terms (46)— hover any for plain English
Limited neck range of motionHP:0000466Photosensitive myoclonic seizureHP:0001327Focal aware seizureHP:0002349Cogwheel rigidityHP:0002396Focal hemiclonic seizureHP:0006813Photosensitive tonic-clonic seizureHP:0007207Atypical absence seizureHP:0007270Obsessive-compulsive traitHP:0008770
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex

Elizabeth Donner — PHASE4

TrialNOT YET RECRUITING
Dec 2025Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS

Byteflies — NA

TrialNOT YET RECRUITING
Sep 2025Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

Assistance Publique - Hôpitaux de Paris

TrialRECRUITING
Jun 2025A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Stoke Therapeutics, Inc — PHASE3

TrialRECRUITING
Oct 2024Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

University of Colorado, Denver — PHASE4

TrialRECRUITING
Sep 2024A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Longboard Pharmaceuticals — PHASE3

TrialRECRUITING
May 2024A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

UCB BIOSCIENCES, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
May 2024A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Encoded Therapeutics — PHASE1, PHASE2

TrialRECRUITING
May 2024A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

Encoded Therapeutics — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Feb 2024A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Encoded Therapeutics — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

Fintepla

fenfluramine· UCB, Inc.■ Boxed Warning

FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older

Epidiolex

CANNABIDIOL· Jazz Pharmaceuticals, Inc.

EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 1 year of age and older

Diacomit

stiripentol· BiocodexOrphan Drug

Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more

Clinical Trials

12 recruitingView all trials with filters →
Phase 34 trials
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Phase 3
Actively Recruiting
PI: Amit Ray, MD (Harmony Biosciences Management, Inc.) · Sites: Los Angeles, California; Orange, California +44 more · Age: 299 yrs
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Phase 3
Actively Recruiting
· Sites: Little Rock, Arkansas; Los Angeles, California +91 more · Age: 265 yrs
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Phase 3
Active
PI: UCB Cares (001 844 599 2273) · Sites: Memphis, Tennessee; Dallas, Texas +10 more · Age: 199 yrs
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Phase 3
Actively Recruiting
· Sites: Phoenix, Arizona; Little Rock, Arkansas +43 more · Age: 217 yrs
Phase 41 trial
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
Phase 4
Actively Recruiting
PI: Kelly Knupp, MD (University of Colorado, Denver) · Sites: San Francisco, California; Aurora, Colorado +1 more
Phase 21 trial
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Phase 2
Active
PI: Ann Dandurand, MD (Medical Director) · Sites: San Francisco, California; Aurora, Colorado +15 more
N/A1 trial
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity
N/A
Enrolling by Invitation
· Sites: Roma · Age: 1835 yrs
Other2 trials
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
Actively Recruiting
PI: Stéphane Auvin, MD, PhD (Assistance Publique Hopitaux de Paris) · Sites: Paris, Ap-hp / DRCI · Age: 021 yrs
GABA Biomarkers in Dravet Syndrome
Actively Recruiting
PI: Christos Papadelis, PhD (Cook Children's Health Care System) · Sites: Fort Worth, Texas · Age: 018 yrs

Specialists

Showing 25 of 31View all specialists →
JM
Joseph Sullivan, MD
Specialist
PI on 1 active trial
KM
Kelly Knupp, MD
AKRON, OH
Specialist
PI on 3 active trials
AM
Alan K Percy, MD
BIRMINGHAM, AL
Specialist
PI on 2 active trials1 Dravet syndrome publication
OM
Orrin Devinsky, MD
NEW YORK, NY
Specialist
PI on 4 active trials
AM
Ann Dandurand, MD
Specialist
PI on 2 active trials
DM
Dennis J Dlugos, MD
PHILADELPHIA, PA
Specialist
PI on 2 active trials
SD
Salvador Rico, M.D., Ph. D
Specialist
PI on 1 active trial
BM
Beverly S Wical, MD
SAINT PAUL, MN
Specialist
PI on 2 active trials
SP
Stéphane Auvin, MD, PhD
Specialist
PI on 1 active trial
HP
Hahn-Jun Lee, Ph.D.
Specialist
PI on 1 active trial
EM
Elaine Wirrel, MD
Specialist
PI on 1 active trial
LM
Liankun Ren, MD
Specialist
PI on 4 active trials1 Dravet syndrome publication
BD
Blandine DOZIERES, Dr
Specialist
PI on 1 active trial
RD
Roland Thijs, Dr.
Specialist
PI on 1 active trial
JM
Joseph Hulihan, MD
NEWTOWN, PA
Specialist
PI on 2 active trials
CD
Catherine J Harmer, DPhil
Specialist
PI on 1 active trial
MB
Meir Bialer
Specialist
2 Dravet syndrome publications
SS
Susanne Schubert-Bast
Specialist
2 Dravet syndrome publications
IS
Ingrid E Scheffer
Specialist
8 Dravet syndrome publications
AS
Amy L Schneider
Specialist
2 Dravet syndrome publications
BC
Berten Ceulemans
Specialist
2 Dravet syndrome publications
VV
Vicente Villanueva
Specialist
2 Dravet syndrome publications
EW
Elaine C Wirrell
ROCHESTER, MN
Specialist
6 Dravet syndrome publications
JC
J Helen Cross
Specialist
5 Dravet syndrome publications
LL
Lieven Lagae
Specialist
5 Dravet syndrome publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

3 resources
Fintepla(fenfluramine)UCB, Inc.
Epidiolex(CANNABIDIOL)Jazz Pharmaceuticals, Inc.
Diacomit(stiripentol)Biocodex

Travel Grants

No travel grants are currently matched to Dravet syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Dravet syndromeForum →

No community posts yet. Be the first to share your experience with Dravet syndrome.

Start the conversation →

Latest news about Dravet syndrome

1 articles
NewsEPILEPSIAMar 26, 2026
Underutilization of syndrome-specific ICD-10 codes for genetic epilepsies: Implications for precision medicine
Published in Epilepsia. Moura Coelho da Silva É et al.
See all news about Dravet syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which medications are safest for my child's type of Dravet syndrome, and which ones should we avoid?,Should we have rescue medication at home, and can you train us on how to use it?,Is genetic testing recommended for other family members, and what does a positive SCN1A result mean for future pregnancies?,What is the risk of SUDEP for my child, and what steps can we take to reduce it?,Would a ketogenic diet be appropriate for my child, and how do we get started?,What developmental therapies and educational supports should we be pursuing right now?,Are there any clinical trials or new treatments we should consider?

Common questions about Dravet syndrome

What is Dravet syndrome?

Dravet syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare and serious form of epilepsy that begins in the first year of life. It is caused by changes (mutations) in a gene that helps brain cells communicate properly. When this gene does not work as it should, the brain becomes overly excitable, leading to frequent and hard-to-control seizures. Children with Dravet syndrome typically start having seizures between 5 and 8 months of age. These early seizures are often triggered by fever or a rise in body temperature. Over time, different types of seizures appear, and

How is Dravet syndrome inherited?

Dravet syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Dravet syndrome typically begin?

Typical onset of Dravet syndrome is infantile. Age of onset can vary across affected individuals.

Are there clinical trials for Dravet syndrome?

Yes — 12 recruiting clinical trials are currently listed for Dravet syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Dravet syndrome?

25 specialists and care centers treating Dravet syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Dravet syndrome?

1 patient support program are currently tracked on UniteRare for Dravet syndrome. See the treatments and support programs sections for copay assistance, eligibility, and contact details.